ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0835

Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Abstract Number: 0836

NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses
Abstract Number: 0837

Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
Abstract Number: 0838

The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Abstract Number: 0839

Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity
Abstract Number: 0840

The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS
Abstract Number: 0841

Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)
Abstract Number: 0842

The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)
Abstract Number: 0843

External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors
Abstract Number: 0844

Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Abstract Number: 0845

Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies
Abstract Number: 0846

Three Novel Metabolomic Signatures of Inflammation for Female Gout Risk: A Prospective Cohort Study over 26 Years
Abstract Number: 0847

Sex and Race-Specific Distributions in Medial Fixed Joint Space Width in Healthy Knees from Three Longitudinal Cohorts
Abstract Number: 0848

Impact of SGLT2i Initiation on the Need for Urate-Lowering Therapy and Colchicine Among Gout Patients with Type 2 Diabetes:Propensity-Score Matched, Active Comparator, New User Design Study
Abstract Number: 0849

Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].